Introduction {#S1}
============

One of the consequences of chronically elevated urea levels in patients with kidney disease is the accelerated chemical modification of proteins by urea (carbamylation).([@R1]-[@R3]) The accumulation of these modifications on albumin (as well as other serum proteins) has been shown to be proportional to blood urea concentrations, in a fashion analogous to the relationship between hemoglobin A~1c~ levels and time-averaged glucose concentrations.([@R4], [@R5]) In addition to chronic uremia, amino acid deficiencies are common in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD),([@R6]) and there is evidence that these amino acid deficiencies may further exacerbate protein carbamylation.([@R3], [@R5]) As a result, the proportion of albumin that is carbamylated (C-Alb) represents a biomarker that simultaneously integrates time-averaged urea concentrations and possibly protein energy wasting in patients on hemodialysis.([@R5])

Recent work has demonstrated a strong and independent association between serum carbamylated protein levels and risk of death in patients on hemodialysis treatment.([@R4], [@R5]) However, the mechanisms linking uremia, protein carbamylation, and mortality remain poorly understood. A number of studies have suggested a direct role for protein carbamylation in the cardiovascular pathology associated with CKD. For example, when nephrectomized ApoE-null mice were fed pure urea in their chow, it dramatically accelerated rates of aortic atherogenesis.([@R7]) It has also been shown that protein carbamylation has pro-atherogenic effects on lipoproteins. Animal studies have shown that uremia increases carbamylation of plasma low density lipoproteins (LDL) and high density lipoproteins (HDL), and this modification inhibits receptor mediated uptake and instead promotes foam cell formation and accumulation in atherosclerotic tissues.([@R8]-[@R13]) A clinical study of patients undergoing cardiac catheterization and age-matched controls further demonstrated that when cases and controls were stratified by their serum carbamylated protein levels, subjects with higher carbamylated protein levels were affected by CVD in greater proportions. ([@R14]) Together these results suggest protein carbamylation may contribute to the cardiovascular disease burden associated with kidney failure.

We recently reported strong independent associations between carbamylated albumin levels and 12 month all-cause mortality in both incident and prevalent hemodialysis patient cohorts, even after adjusting for other significant risk factors ([@R5]) In order to test whether C-Alb values are also associated with longer-term outcomes, herein we describe analysis of 4-year risk of death from specific causes associated with C-Alb. Furthermore, in order to search for specific pathologic sequelae associated with carbamylation, we re-analyzed the study database for associations between C-Alb and co-existing comorbidities as well as future risk of death from specific causes. In addition, in light of previous studies suggesting a connection between protein carbamylation and atherogenesis, we investigated the relationship between C-Alb, serum cholesterol levels, and survival benefits from atorvastatin therapy.

Results {#S2}
=======

Associations between carbamylated albumin levels, clinical laboratory tests, and co-existing comorbidities {#S3}
----------------------------------------------------------------------------------------------------------

Baseline differences in clinical, demographic, and biochemical characteristics were compared in 4D subjects according to their tertile of baseline C-Alb levels (tertile 1: C-Alb \<0.72, tertile 2: C-alb between 0.72 and 0.90, tertile 3: C-alb \> 0.90). The mean length of follow-up was 3.96 years in the atorvastatin group and 3.91 years in the placebo group. As shown in [Table 1](#T1){ref-type="table"}, analysis of variation found associations between higher tertile C-Alb levels and higher pre- and post-dialysis blood urea and creatinine levels. High C-Alb was also associated with elevated phosphate and potassium levels and lower urea reduction ratio values. These findings are consistent with the hypothesis that chronic uremia and lower efficiency of urea reduction therapy may be contributing to increased protein carbamylation. High C-Alb was also associated with higher average NT-Pro-BNP, troponin T, intact PTH, alkaline phosphatase, and HDL cholesterol, and with lower average body mass index, lower total cholesterol, lower hemoglobin, and low ferritin. Baseline C-Alb also showed modest correlations with troponin T (*r* = +0.183, p\<0.001) and NT-proBNP (*r* = +0.227, p\<0.001). The data set was further analyzed for associations between high C-Alb levels and co-existing co-morbidities, revealing that high C-Alb was associated with current diagnosis of congestive heart failure, atrial fibrillation, and hypertension. In contrast, there were no significant associations between high C-Alb and history of coronary artery disease, peripheral vascular disease, or cerebrovascular disease.

Associations between carbamylated albumin levels and specific 1-year adverse events {#S4}
-----------------------------------------------------------------------------------

4D subjects' baseline C-Alb values were analyzed for associations with 1-year risk of specific adverse outcomes using multivariable-adjusted Cox proportional hazards models. As shown in [Table 2](#T2){ref-type="table"}, higher baseline C-Alb values were found to be strongly associated with univariate risk of death from all causes, CV and non-CV mortality. The effect was strongest for CV mortality; in particular for sudden cardiac death. The risks associated with C-Alb were adjusted for potentially confounding variables, including age, time on dialysis therapy (dialysis vintage), systolic and diastolic blood pressure, serum albumin, phosphate, parathyroid hormone, cholesterol, HDL-C, hemoglobin, C-reactive protein, potassium, creatinine, NT-proBNP, troponin T, treatment with ACE inhibitors/calcium antagonists/diuretics, history of hypertension, and history of CVD (including CAD, CHF, PVD). After adjusting for all these variables, it was still found that the risk of sudden cardiac death, all-cause mortality and cardiovascular mortality remained significant. Interestingly, there was no specific association between C-Alb values and risk of myocardial infarction.

We performed a sensitivity analysis in the subset of patients with available URR values (n=471). We compared the hazard ratios for 1 year mortality when a) adjustments were made for all variables mentioned above and b) additional adjustments were made for URR. Of note, in both analyses, the risks were similar with hazard ratios of a) 1.77 (0.92-3.40) and b) 1.78 (0.92-3.42), reassuring that URR is unlikely to act as a confounding parameter in our study.

Associations between carbamylated albumin levels and specific 4-year adverse events {#S5}
-----------------------------------------------------------------------------------

4D subjects' baseline C-Alb values were analyzed for associations with 4-year risk of specific adverse outcomes using multivariable-adjusted Cox proportional hazards models. As shown in [Table 2](#T2){ref-type="table"}, higher baseline C-Alb values were found to be strongly associated with univariate risk of CV and all-cause mortality. Notably, there was an especially strong association between initial C-Alb values and risk of death from congestive heart failure (HR 7.26 (2.18 -- 24.16), p=0.001) and a significant association with sudden cardiac death (HR 2.29 (CI 1.23-4.24)). HR estimates were again calculated using a Cox proportional hazards model adjusted for the potential confounders mentioned above; the risk of death from congestive heart failure, sudden cardiac death, CV and all-cause mortality remained significant even after accounting for these other risk factors.

Lastly, although our multivariable model was adjusted for the effects of many potential confounders, in order to further exclude the possibility that co-morbid conditions may have confounding effects on the association between C-Alb values and risk of death, we re-analyzed our data after stratifying subjects according to presence or absence of a variety of baseline risk factors (including history of hypertension, CAD, CHF, arrhythmias; see [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). Furthermore, because of the observed association between high C-Alb values and shorter times on dialysis, we also wanted exclude the possibility that differences in dialysis vintage were confounding the association between C-Alb and mortality. Using these stratified analyses, we observed that C-Alb was still significantly associated with 1-year and 4-year mortality in patients with longer or shorter histories of dialysis therapy and in patients with or without past histories of CHF, CAD, or arrhythmia ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}), indicating that the risks associated with C-Alb were not simply due to associations with these preexisting conditions. Although the 1-year and 4-year risks in patients with no history of hypertension were not statistically significant (HR 2.89 (0.44 -- 18.99, p=0.268) and HR 0.90 (0.37 -- 2.18, p=0.813), respectively), this may in part be due to the relatively small size of this subgroup (n=133).

Effects of atorvastatin therapy on survival in subjects stratified by carbamylated albumin levels {#S6}
-------------------------------------------------------------------------------------------------

In [Table 1](#T1){ref-type="table"} an association was noted between high C-Alb levels and lower serum total cholesterol and higher HDL cholesterol concentrations. A similar analysis was performed on study data from 186 incident hemodialysis patients (with and without histories of diabetes mellitus) who participated in the ArMORR study and whose characteristics were previously described.([@R5]) Analysis of serum samples collected at baseline from this independent cohort observed a negative correlation between C-Alb and total serum cholesterol levels (*r* = -0.29, p\<0.001). Given the inverse association between serum carbamylated albumin and total cholesterol and the association between C-Alb and mortality, we speculated whether uremia and carbamylation may be modifying the associations between hypercholesterolemia, response to statin therapy, and cardiovascular risk seen in most populations. In order to test this, we sought to determine whether atorvastatin therapy influenced survival in subjects that were first stratified according to their baseline C-Alb values. Baseline characteristics in subjects grouped by treatment arm and low baseline C-Alb values are shown in [Table 3](#T3){ref-type="table"}. Although there were no survival benefits associated with atorvastatin therapy in subjects in the upper or middle tertile for carbamylated albumin, there was a statistically significant decrease in mortality in subjects with low baseline carbamylated albumin that were treated with atorvastatin (HR 0.692 (CI 0.505 -- 0.947, p = 0.022)) ([Table 4](#T4){ref-type="table"}). Note that subjects in the lower tertile for C-Alb values that were randomized to atorvastatin therapy had slightly higher average LDL cholesterol levels at baseline compared to placebo controls (122 vs. 128, p\<0.033).

Discussion {#S7}
==========

In this study of patients with diabetic end stage kidney disease receiving maintenance hemodialysis we found that elevated serum protein carbamylation is associated with increased serum markers of cardiac stress, as well as increased CV mortality; in particular short-term risk of sudden death and long-term risk of death from congestive heart failure. High C-Alb levels were strongly associated with 4-year risk of death due to heart failure but not associated with 1-year risk; in contrast, there was significant risk of sudden cardiac death associated with high C-Alb levels during the first year of follow-up, but the estimated risk decreased after 4-years of follow-up. We interpreted the risk of sudden cardiac death to be consistent with the hypothesis that cardiac protein "hypercarbamylation" represents an acute insult to the cardiac conduction system which may be reversible if carbamylation is reduced, and thus the risk diminishes over time. We interpreted the long-term risk of heart failure to be consistent with the hypothesis that carbamylation is contributing to uremic cardiomyopathy and fibrosis which are irreversible but take time to progress before fulminant cardiac failure occurs. There were no associations to history of coronary artery disease or future risk of myocardial infarction, however. Interestingly, low C-Alb values were associated with modestly increased total cholesterol, and when subjects were stratified by C-Alb tertile, subjects with lower, C-Alb values responded to atorvastatin treatment with longer survival times compared to patients given placebo. Together these findings may suggest clues as to the mechanistic connections between uremia, protein carbamylation, and cardiac pathology in patients on hemodialysis. If these findings can be confirmed in other populations, protein carbamylation may represent a viable therapeutic target to modify cardiovascular risk in end-stage kidney disease patients.

The majority of ESRD patients die of cardiac causes, and the two most common causes of death in ESRD patients on hemodialysis are from sudden cardiac death and myocardial infarction (MI). ([@R15], [@R16]) Although atherosclerosis is accelerated in patients with kidney disease ([@R17], [@R18]), the pathogenesis of coronary artery disease in patients with kidney failure differs in important ways from the mechanisms of atherogenesis found in patients with normal kidney function. Coronary artery disease in patients with kidney disease is characterized by a combination of atherosclerotic changes combined with progressive calcification (calcific arteriosclerosis), but cholesterol-lowering therapies have not been shown to reduce the risk of myocardial infarctions in these patients. ([@R19]-[@R21]) These observations have prompted some to suggest that mechanisms other than hypercholesterolemia are responsible for the accelerated atherosclerosis and arteriosclerosis associated with ESRD---mechanisms including carbamylation ([@R3], [@R22]-[@R24]). Our data do not appear to support the hypothesis that accelerated atherosclerosis of uremia may be mediated by carbamylation.

Previous studies have suggested that the pathophysiology of sudden death in dialysis patients is due to fatal arrhythmias unrelated to CAD. ([@R15]) The risk factors for sudden death in hemodialysis patients are more commonly associated with dialysis-associated electrolyte imbalances, hyperkalemia, hyperphosphatemia, and "uremic cardiomyopathy," ([@R25]) Uremic cardiomyopathy is thought to be caused by the effects of cardiac toxins that accumulate in renal failure, and is characterized by left ventricular hypertrophy (LVH), cardiac conduction abnormalities, progressive myocardial fibrosis with myocyte dropout and congestive heart failure, and may be reversible by improvements in patients' dialysis therapy. ([@R22], [@R25]-[@R28]) It has been suggested that uremic cardiomyopathy is just as important a contributor to mortality in dialysis patients as atheromatous CAD, and our results suggest that hypercarbamylation is associated with this process.([@R25]) Animal studies are needed to evaluate whether protein carbamylation is causally related to uremic cardiomyopathy and congestive heart failure.

In this study, we observed an association between high C-Alb and low total cholesterol levels, and the association between higher serum carbamylated protein levels and lower serum total cholesterol in patients on hemodialysis has been reported previously. ([@R4]) Low cholesterol levels in ESRD patients have been linked to anemia, hypoalbuminemia, low BMI, and protein energy wasting, and are paradoxically associated with increased mortality in ESRD. ([@R29]-[@R31]) In the current study and our previous report, C-Alb was also associated with anemia, lower BMI, amino acid deficiencies, and increased mortality. Furthermore, the association between low cholesterol and mortality in these patients may be the reason why it is difficult to show any measurable benefits of cholesterol-lowering therapy in ESRD patients. ([@R20], [@R21]) Most interestingly, in contrast to the original findings of the 4D study, when we stratified 4D patients according to C-Alb levels, we found that patients with low C-Alb levels in fact did show a survival benefit in response to atorvastatin. Together these findings suggest that ESRD patients whose protein carbamylation levels are already well controlled may benefit from cholesterol-lowering therapies. The reasons why patients with low C-Alb responded to atorvastatin are unknown, but we speculate that in patients with high C-Alb, the detrimental effects of excessive protein carbamylation overwhelm any benefits of statins in these patients (who already tended to have low cholesterol levels at baseline), whereas patients with low C-Alb values benefited from atorvastatin in the same way as non-uremic patients would. Although additional studies are needed to corroborate these findings, these results suggest that an identifiable subset of hemodialysis patients may benefit from statin therapy. ([@R32])

A number of human and animal model studies have demonstrated pro-atherogenic effects of carbamylated lipoproteins. ([@R7]-[@R13]) It was somewhat unexpected, therefore, that our study found no significant association between C-Alb and risk of myocardial infarction or stroke. One explanation for this is that subjects with high C-Alb levels had lower total cholesterol and higher HDL cholesterol levels. A second possible explanation is that lipoproteins are carbamylated by a different mechanism than that of albumin, and as a result the risks associated with these two markers are also distinct. Although uremia promotes carbamylation of LDL (cLDL), another potentially important source of lipoprotein carbamylation is myeloperoxidase (MPO) activity within atherosclerotic plaques.([@R7], [@R14]) Large amounts of MPO are secreted by foam cells, and lipoprotein carbamylation is strongly enriched within atheromas, suggesting that carbamylation of lipoproteins may be occurring locally within the plaques. ([@R12]-[@R14]) Circulating cLDL levels are correlated with MPO, whereas there is no correlation between MPO and C-Alb3 ([@R5], [@R33]) Together these findings suggest that there are differences between the mechanisms of carbamylation of lipoproteins and other circulating proteins, and these differences may provide insight into different pathophysiologies and risks associated with uremia.

There are several limitations to our study. All study subjects had histories of diabetes mellitus, raising the possibility that the findings apply mostly to patients with diabetic kidney disease. Our study was missing samples for 124 out of 1285 of the subjects; although there was no survival difference between the missing subjects and the cohort as a whole, this introduces the possibility of drop-out bias. Although our results show significant associations between C-Alb and short-term risk of sudden cardiac death and long-term risk of death due to heart failure, our findings are correlational and they do not conclusively demonstrate that carbamylation is the cause of uremic heart disease and death. Although elevated C-Alb values were strongly associated with CV mortality, there was no significant independent association with non-CV mortality, as might be expected if carbamylation contributes to other risks associated with uremia. Furthermore, although we were able to adjust for many possible confounding variables in our hazards model, and could show that C-Alb retained its association to survival risk even after stratifying for histories of CHF, atrial fibrillation, CAD/MI, and hypertension, we cannot fully exclude residual confounding. In particular, elevated C-Alb levels may be a sign of insufficient dialysis, but we could not adjust for Kt/V because these data were not available. However, we performed sensitivity analyses in the subset of 471 patients with available URR and foundno difference in risk after adjusting for URR, making any confounding effects by this variable unlikely. Lastly, although we did not have enough sample for additional analyses, it would be informative to know if other tests for serum protein carbamylation such as protein-bound homocitrulline ([@R4]) also demonstrate the same specific associations to cardiac mortality in patients with uremia. The strengths of this study include: (1) relatively large size of the study (n=1,161), (2) detailed longitudinal outcomes data based upon pre-specified criteria and panel adjudication, (3) availability of many clinical covariates, (4) availability of 4 years of follow-up which enabled us to demonstrate both short-term and long-term risks associated with C-Alb.

In summary, a secondary analysis of study data from 1,161 diabetic patients on hemodialysis revealed associations between C-Alb values and risk of future cardiac sequelae; the risks of sudden death and heart failure, and the lack of association to myocardial infarction provide clues to specific mechanisms connecting protein carbamylation and uremic cardiomyopathy. The risk of CV mortality, in particular sudden death and heart failure associated with baseline C-Alb remained strong even 4 years after C-Alb was measured, suggesting long-term prognostic value of this new biomarker. Lastly, we discovered that patients on hemodialysis with low C-Alb values demonstrated a statistically significant prolongation of survival when treated with atorvastatin, suggesting that measurement of protein carbamylation burden may represent a novel way to identify the subset of ESRD patients that would benefit from this well-established therapy.

Materials and Methods {#S8}
=====================

Materials {#S9}
---------

All chemicals, except when noted, were purchased from Sigma-Aldrich.

### Study Populations {#S10}

Frozen specimens from 1,161 subjects of Die Deutsche Diabetes Dialyze Studie (4D trial) were used for analysis.([@R20], [@R34]) The 4D study was a prospective randomized controlled trial of the effects of atorvastatin on mortality that included 1,255 patients with type 2 diabetes mellitus, aged 18-80 years, receiving hemodialysis for less than 2 years. Between March 1998 and October 2002, patients were recruited in 178 dialysis centres in Germany. After a period of 4 weeks, patients were randomly assigned to double-blinded treatment with either 20mg atorvastatin (n=619) or placebo (n=636) once daily. Study visits took place three times before randomization (visit 1-3), at randomization (visit 4), and at four weeks (visit 5) and every six months (visit 6 etc.) after randomization until the date of death, censoring, or end of the study in March 2004. 4D specimens analyzed for this study were obtained 1 week prior to treatment randomization, after which subjects were followed every 6 months until the date of death, censoring, or end of the study. 4D specimens were stored at -80°C until analysis. The study was conducted in accordance with ethical standards and approved by the institutional medical ethical committee, and all patients gave written informed consent before inclusion. Information for age, sex, and smoking status was obtained through patient interviews. Comorbid conditions, including the presence of coronary artery disease and congestive heart failure, as well as duration of diabetes mellitus and dialysis treatment, were reported by patients' nephrologists. Blood pressure was measured in the sitting position during their first study visit. 124 of the original 1,255 subjects had insufficient specimen for analysis, leaving 1,161 samples available for our analysis; the mortality rate of this missing subgroup did not differ from the rest of the cohort (48% vs. 49%, p=0.836). Outcome assessment methods were described in the original 4D study. ([@R20], [@R34])The study end points and serious adverse events were continuously monitored; every end point was adjudicated by three members of the end-point committee on the basis of predefined criteria detailed in ([@R35]). Death from cardiac causes was subdivided into categories including fatal myocardial infarction, sudden death, death due to congestive heart failure, and death due to coronary heart disease within 28 days after an intervention. Patients who died unexpectedly and did not meet criteria for other types of cardiac death were considered to have had sudden death from cardiac causes. For the present analysis, CV mortality, sudden death, MI (fatal and non-fatal), stroke (fatal and non-fatal), all-cause mortality and deaths due to infection were all chosen as separate outcome measures.

### Biochemical analyses of carbamylated albumin {#S11}

Biochemical measurements of C-Alb levels in the 4D cohort were performed and reported previously that analyzed the association between C-Alb and 12 month all-cause mortality; a complete description of the mass spectrometric assay for carbamylated albumin (C-Alb) and its analytical validation are described in this previous report.([@R5]) All carbamylated albumin values are reported in terms of the percentage of carbamylated relative to non-carbamylated albumin. Repeat measurements of a representative patient sample demonstrated a coefficient of variance (CV) of 4.2%.

### Other biochemical analyses {#S12}

All clinical blood tests for troponin T, NT-proBNP, and other biochemical markers were performed during the original 4D study by the 4D central laboratory in blood samples obtained at baseline during study visit 3 (1 week before randomization).([@R34])

Statistical Analysis {#S13}
--------------------

SPSS software, version 21 (IBM), was used for all analyses. Comparisons between characteristics of subject groups were analyzed using Student's t-test, Analysis of Variation, Mann-Whitney-U tests, or Chi-Squared Tests where appropriate. Correlations between variables were calculated using the Pearson product-moment correlation coefficient. Analysis of sudden cardiac death, myocardial infarction, stroke, death due to heart failure, combined cardiovascular events and infectious deaths were performed with the use of Cox proportional-hazards (HR) models. Proportional hazard assumptions were checked for all HR models. C-Alb values were transformed to their natural log and analyzed as a continuous variable for HR analysis. To analyze for associations between C-Alb levels and benefits of atorvastatin therapy, subjects were stratified into tertiles according to their C-Alb values, and independent HR analyses were performed for each tertile. Two-tailed P-values of \<0.05 were considered significant.
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###### 

Baseline clinical and laboratory data for study population categorized by carbamylated albumin tertile

  Baseline characteristic                                     Carbamylated albumin tertile   *P*-value                      
  ----------------------------------------------------------- ------------------------------ -------------- --------------- ---------
  Age (*years*)                                               65 ± 9                         66 ± 8         66 ± 8          0.099
  Male                                                        52                             57             54              0.364
  Proportion of subjects receiving atorvastatin               46.0% (178)                    50.6% (196)    50.9% (197)     0.307
  Duration of dialysis (months)                               9.3 ± 7.1                      8.3 ± 6.9      7.2 ± 6.4       \<0.001
  Pre-dialysis BUN (mg/dL)                                    102 ± 54                       121 ± 61       139 ± 65        \<0.001
  Post-dialysis BUN (mg/dL)[\*](#TFN2){ref-type="table-fn"}   38 ± 19                        51 ± 26        54 ± 27         \<0.001
  Urea reduction ratio (%)[\*](#TFN2){ref-type="table-fn"}    64 ± 9                         60 ± 14        61 ± 10         0.011
  Creatinine (mg/dL)                                          6.6 ± 2.2                      7.0 ± 2.2      7.0 ± 2.4       0.004
  Systolic blood pressure (*mmHg*)                            145 ± 22                       146 ± 22       146 ± 22        0.850
  Diastolic blood pressure (*mmHg*)                           76 ± 11                        76 ± 11        76 ± 11         0.934
  BMI (*kg/m^2^*)                                             28.2 ± 4.8                     27.2 ± 4.5     27.0 ± 4.9      0.001
  Alkaline phosphatase (*IU/L*)                               121 ± 50                       119 ± 50       133 ± 80        0.003
  Troponin T (ng/mL)                                          0.07 ± 0.11                    0.08 ± 0.10    0.10 ± 0.12     0.006
  NT-Pro-BNP (pg/mL)                                          5886 ± 9676                    7776 ± 14697   10754 ± 15431   \<0.001
  Creatinine kinase (U/L)                                     66 ± 70                        69 ± 55        72 ± 51         0.336
  C-reactive protein (ng/mL)                                  10.8 ± 15.1                    9.4 ± 13.0     11.6 ± 22.2     0.202
  Total cholesterol (*mg/dL*)                                 224 ± 42                       220 ± 43       215 ± 42        0.016
  LDL cholesterol (*mg/dL*)                                   124 ± 28                       126 ± 29       127 ± 31        0.400
  HDL cholesterol (*mg/dL*)                                   34 ± 12                        36 ± 13        39 ± 15         \<0.001
  Albumin (*g/dL*)                                            3.81 ± 0.3                     3.84 ± 0.3     3.82 ± 0.3      0.354
  Hemoglobin (*g/L*)                                          11.1 ± 1.3                     10.9 ± 1.3     10.7 ± 1.3      0.004
  Transferrin saturation (*%*)                                22.9 ± 12.1                    22.6 ± 10.9    21.1 ± 11.1     0.054
  Calcium (*mmol/L*)                                          2.33 ± 0.21                    2.30 ± 0.20    2.29 ± 0.24     0.007
  Ferritin (*pmol/L*)                                         537 ± 461                      480 ± 429      450 ± 384       0.016
  Potassium (*mmol/L*)                                        5.1 ± 0.9                      5.1 ± 0.8      5.3 ± 0.8       0.007
  Phosphorus (*mg/dL*)                                        5.6 ± 1.4                      6.1 ± 1.6      6.4 ± 1.7       \<0.001
  Platelets (*10^3^/μL*)                                      256 ± 76                       254 ± 76       261 ± 87        0.490
  Intact parathyroid hormone (*ng/L*)                         93 ± 122                       100 ± 101      115 ± 139       0.041
  White blood cells (*10^3^/μL*)                              8.0 ± 2.3                      8.0 ± 2.3      8.4 ± 2.7       0.060
  Aspartate aminotransferase (*IU/L*)                         14 ± 6                         14 ± 16        14 ± 7          0.890
  HbA~1c~ (%)                                                 6.7 ± 1.2                      6.7 ± 1.3      6.7 ± 1.3       0.847
  Duration of diabetes (*years*)                              17 ± 9                         18 ± 9         19 ± 9          0.162
  *Prevalence of comorbid conditions present at baseline*                                                                   
   Congestive heart failure                                   32.8% (127)                    31.0% (120)    35.6% (166)     0.001
   Atrial fibrillation                                        17.1% (66)                     16.0% (62)     22.5% (87)      0.046
   Hypertension                                               84.8% (328)                    90.4% (350)    90.7% (351)     0.013
   Coronary artery disease                                    27.7% (107)                    28.7% (111)    33.3% (129)     0.184
   Peripheral vascular disease                                45.7% (177)                    44.4% (172)    44.7% (173)     0.930
   Cerebrovascular accident                                   18.9% (73)                     18.3% (71)     16.0% (62)      0.545
  Blood pressure medication                                                                                                 
   ACE inhibitors                                             45.2% (175)                    48.1% (186)    49.9% (193)     0.426
   Calcium antagonists                                        35.1% (136)                    41.6% (161)    45.5% (176)     0.013
   Diuretics                                                  78.8% (305)                    78.0% (302)    82.9% (321)     0.186
   Beta blockers                                              38.5% (149)                    39.5% (153)    36.2% (140)     0.615

Data are expressed as mean ± SD for continuous variables and percentages (%) with number of cases for categorical data. Analysis of variance was used to test for differences between groups for continuous variables, Chi square testing was used to test for significant differences between proportions for categorical variables.

Post-dialysis urea and urea reduction ratio values were available for 471 of the 1,1161 subjects.

###### 

Association between baseline carbamylated albumin[\*](#TFN3){ref-type="table-fn"} and 1-year and 4-year risk of death from specific causes

  Cause of death                                        *Unadjusted*           *MV-adjusted*[1](#TFN4){ref-type="table-fn"}                          
  ----------------------------------------------------- ---------------------- ---------------------------------------------- ---------------------- -------
   **1-year risk of adverse events**                                                                                                                 
  All-cause mortality (n = 138)                         3.73 (2.00 -6.96)      \<0.001                                        2.74 (1.35 -- 5.57)    0.005
  Sudden death (n = 45)                                 5.26 (1.78 -- 15.57)   0.003                                          3.78 (1.18 -- 12.10)   0.025
  Congestive heart failure (n=14)                       5.23 (0.75 -- 36.59)   0.096                                          2.44 (0.24 -- 25.27)   0.455
  Myocardial infarction (n = 48)                        1.22 (0.42 -- 3.55)    0.721                                          1.33 (0.41 -- 4.37)    0.637
  Cerebrovascular accident (n = 33)                     0.76 (0.21 -- 2.77)    0.672                                          0.52 (0.12 -- 2.34)    0.397
  Infection (n = 22)                                    2.30 (0.48 -- 11.11)   0.300                                          1.28 (0.19 -- 8.38)    0.801
  CV mortality[2](#TFN5){ref-type="table-fn"} (n=84)    3.97 (1.78-8.82)       0.001                                          3.06 (1.25-7.46)       0.014
  Non-CV mortality (n=54)                               3.38 (1.24-9.19)       0.017                                          2.43 (0.76-7.82)       0.137
   **4-year risk of adverse events**                                                                                                                 
  All-cause mortality (n = 572)                         1.86 (1.35 -2.55)      \<0.001                                        1.43 (1.01 -2.05)      0.047
  Congestive heart failure (n=38)                       7.26 (2.18 -- 24.16)   0.001                                          4.64 (1.11-19.51)      0.036
  Sudden death (n = 150)                                2.29 (1.23 -4.24)      0.009                                          1.78 (0.91-3.50)       0.095
  Myocardial infarction (n = 181)                       1.63 (0.92 -- 2.86)    0.089                                          1.25 (0.66 -- 2.35)    0.494
  Cerebrovascular accident (n = 97)                     1.71 (0.80 -- 3.69)    0.169                                          1.37 (0.57 -- 3.28)    0.480
  Infection (n = 118)                                   1.84 (0.91 -- 3.70)    0.089                                          1.50 (0.69 -- 3.26)    0.307
  CV mortality[2](#TFN5){ref-type="table-fn"} (n=286)   2.47 (1.58-3.87)       \<0.001                                        1.90 (1.15-3.13)       0.013
  Non-cardiac mortality (n=286)                         1.39 (0.88-2.18)       0.154                                          1.07 (0.65-1.77)       0.797

Cox proportional hazards model of association between baseline carbamylated albumin (log-transformed continuous variable) and 1-year risk of adverse events.

MV-adjusted hazards model was adjusted for potential confounders, including age, dialysis vintage, systolic and diastolic blood pressure, body mass index, albumin, cholesterol, HDL-C, hemoglobin, C-reactive protein, potassium, phosphate, creatinine, parathyroid hormone, NT-proBNP, troponin T, treatment with ACE inhibitors/calcium antagonists/diuretics, history of hypertension, and history of CVD (including CAD, CHF, PVD).

CV mortality included sudden cardiac death, death due to congestive heart failure, death due to myocardial infarction, or any other deaths ascribed to coronary heart disease.

###### 

Baseline characteristics of study population categorized by baseline C-Alb values and Atorvastatin treatment arm

                                        All subjects   Subjects in low tertile for C-Alb                                        
  ------------------------------------- -------------- ----------------------------------- ------- ------------- -------------- -------
  Age (*years*)                         66 ± 8         66 ± 8                              0.811   65 ± 8        65 ± 9         0.634
  Male                                  54             55                                  0.800   52            52             0.985
  Systolic blood pressure (*mmHg*)      145 ± 22       146 ± 22                            0.425   144 ± 22      146 ± 22       0.331
  Diastolic blood pressure (*mmHg*)     76 ± 11        76 ± 11                             0.718   76 ± 11       76 ± 11        0.830
  BMI (*kg/m^2^*)                       27.4 ± 5.0     27.5 ± 4.6                          0.921   28.3 ± 5.2    28.1 ± 4.4     0.723
  Alkaline phosphatase (*IU/L*)         124 ± 57       126 ± 67                            0.591   124 ± 54      118 ± 44       0.222
  Troponin T (ng/mL)                    0.09 ± 0.11    0.09 ± 0.11                         0.737   0.07 ± 0.08   0.08 ± 0.14    0.171
  NT-Pro-BNP (pg/mL)                    8666 ± 15402   7600 ± 11544                        0.184   5502 ± 8854   6333 ± 10564   0.401
  Creatinine kinase (U/L)               69 ± 59        69 ± 60                             0.941   65 ± 70       67 ± 69        0.817
  C-reactive protein (ng/mL)            10.9 ± 18.0    10.3 ± 16.5                         0.567   11.4 ± 16.4   10.0 ± 13.6    0.376
  Total cholesterol (*mmol/L*)          220 ± 41       219 ± 43                            0.860   220 ± 40      228 ± 43       0.069
  LDL cholesterol (*mmol/L*)            127 ± 30       125 ± 29                            0.374   122 ± 26      128 ± 29       0.033
  HDL cholesterol (*mmol/L*)            37 ± 14        36 ± 13                             0.241   34 ± 11       35 ± 12        0.563
  Albumin (*g/L*)                       3.83 ± 0.3     3.80 ± 0.3                          0.098   3.81 ± 0.3    3.81 ± 0.3     0.977
  Hemoglobin (*g/L*)                    10.9 ± 1.4     10.8 ± 1.3                          0.267   11.1 ± 1.4    11.0 ± 1.3     0.491
  Transferrin saturation (*%*)          22.4 ± 10.8    21.9 ± 12.0                         0.465   22.8 ± 11.4   23.1 ± 13.0    0.806
  Calcium (*mmol/L*)                    2.3 ± 0.2      2.3 ± 0.2                           0.736   2.3 ± 0.2     2.4 ± 0.2      0.040
  Ferritin (*pmol/L*)                   492 ± 425      486 ± 429                           0.812   537 ± 461     537 ± 461      0.998
  Potassium (*mmol/L*)                  5.1 ± 0.8      5.2 ± 0.9                           0.341   5.1 ± 0.8     5.1 ± 0.9      0.508
  Phosphorus (*mmol/L*)                 6.0 ± 1.6      6.0 ± 1.6                           0.819   5.6 ± 1.4     5.5 ± 1.4      0.644
  Platelets (*10^3^/μL*)                259 ± 81       255 ± 79                            0.428   257 ± 75      256 ± 79       0.858
  Intact parathyroid hormone (*ng/L*)   102 ± 126      103 ± 119                           0.887   95 ± 141      90 ± 95        0.684
  White blood cells (*10^3^/μL*)        8.2 ± 2.5      8.1 ± 2.4                           0.547   8.0 ± 2.3     7.9 ± 2.2      0.640
  Urea reduction rate (*%*)             62 ± 11        62 ± 12                             0.507   64 ± 10       64 ± 10        0.843
  Aspartate aminotransferase (*IU/L*)   14 ± 7         14 ± 13                             0.727   14 ± 7        14 ± 5         0.268
  HbA~1c~ (*%*)                         6.7 ± 1.3      6.7 ± 1.2                           0.517   6.7 ± 1.3     6.8 ± 1.2      0.816
  Duration of diabetes (*years*)        18.8 ± 8.9     17.4 ± 8.7                          0.008   17.8 ± 8.6    16.9 ± 8.6     0.334

Data are expressed as mean ± SD for continuous variables and percentages (%) with number of cases for categorical data. Student's t-test was used to test for differences between groups for continuous variables, Chi square testing was used to test for significant differences between proportions for categorical variable

###### 

Effects of atorvastatin therapy on 4-year risk of death from all causes in patients stratified according to baseline C-Alb levels.

  C-Alb tertile   HR      95% CI           *P-value*
  --------------- ------- ---------------- -----------
  Bottom          0.692   0.505 -- 0.947   0.022
  Middle          0.935   0.703 -- 1.243   0.624
  Top             1.054   0.808 -- 1.373   0.700

Cox proportional hazards model of association between treatment group (atorvastatin vs. placebo control) and 4-year risk of death from all causes.
